This product is only available in select locations. Please select the location where you would like this product to be shipped to see availability.
Illumina Connected Insights-Annual Subscription
20090137
Illumina Connected Insights‒Oncology Genome Equivalent Sample-VCF
20090138
Illumina Connected Insights‒Training and Onboarding
20092376
Informatics Professional Services
20071787
The TruSight Oncology 500 High-Throughput assay is built on the foundation of the TruSight Oncology 500 assay, with flexibility for higher sample throughput and batching options.
Consolidate Multiple Biomarker Assays into One
Streamlined Sample-to-Results Workflow
High Sample Throughput
Achieve Highly Confident Results
Enable In-House Comprehensive Genomic Profiling
Automation
Automation is available on the Beckman Coulter i-Series or the Hamilton Microlab STAR.
†NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.
‡Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
All three TruSight Oncology 500 assays are designed to identify key biomarkers in guidelines and clinical trials.
Assess key cancer biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.
Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.
Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.
Interested in learning more about the TSO 500 portfolio of products? Download the overview brochure.
TruSight Oncology 500 High-Throughput | TruSight Oncology 500 | TruSight Oncology 500 ctDNA v2 | |
---|---|---|---|
Cancer Type | Pan-Cancer | Pan-Cancer | Pan-Cancer, Solid Tumor |
Content Specifications | Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Immuno-oncology Biomarker Coverage: TMB and MSI • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 600 clinical trials* |
||
Hands-On Time | Manual: ~10.5 hrs Automated: ~2.5 hrs |
Manual: ~10.5 hrs Automated: ~2.5 hrs (TruSight Oncology 500 only), Manual: ~10.5 hrs Automated: ~2.5 hrs (TruSight Oncology 500 only) |
|
Input Quantity | 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue) | 40 ng DNA, 40 ng RNA | |
Method | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing |
Nucleic Acid Type | RNA, DNA | RNA, DNA | DNA |
Sample Throughput | 16–192 samples per flow cell | ||
Specialized Sample Types | FFPE Tissue | FFPE Tissue | Blood, Circulating Tumor DNA |
Species Category | Human | Human | Human |
System Compatibility | NovaSeq 6000, NovaSeq 6000Dx in Research Mode | NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode | NovaSeq 6000 |
Technology | Sequencing | Sequencing | Sequencing |
Variant Class | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants | Copy Number Variants (CNVs), Insertions-Deletions (indels), Single Nucleotide Variants (SNVs) |
Variant Class Details | For TruSight Oncology 500 HRD, genomic instability score, and the following beta features - tumor fraction, tumor ploidy, absolute copy number, and gene-level loss of heterozygosity - are available. Beta features have not been verified by Illumina. See the v2.5+ customer release notes for more details. | For TruSight Oncology 500 HRD, genomic instability score, and the following beta features - tumor fraction, tumor ploidy, absolute copy number, and gene-level loss of heterozygosity - are available. Beta features have not been verified by Illumina. See the v2.5+ customer release notes for more details. |
* Based on Velsera clinical knowledgebase, as of February 2023.
† NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.
Simplifying the process to identify applicable variants in oncology samples
Brochure | PDF 2 MB
Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput
Technical Note | PDF < 1 MB
Data analysis and reporting for the TruSight Oncology 500 portfolio
Product Information Sheet | PDF 1 MB
Simply better variant calling with DRAGEN analysis
Product Information Sheet | PDF < 1 MB
Automating TruSight Oncology 500 High-Throughput
Technical Note | PDF < 1 MB
Data Sheet | PDF | 7 versions
DRAGEN TruSight Oncology 500 Analysis Software v2.5.2 Documentation
TruSight Oncology 500 v2.0 Local App Documentation
TruSight Oncology 500 High Throughput Consumables & Equipment Documentation
DRAGEN TruSight Oncology 500 Analysis Software v1.1 Documentation
TruSight Oncology 500 v1.0 Local App Documentation
TruSight Oncology 500 v2.1 Local App Documentation
DRAGEN TruSight Oncology 500 Analysis Software v2.1 Documentation
TruSight Oncology 500 High Throughput Reference Guide Documentation
DRAGEN TruSight Oncology 500 Analysis Software v2.1.2 on ICA Documentation
DRAGEN TruSight Oncology 500 Analysis Software v1.1 on ICA Documentation
TruSight Oncology 500 High Throughput Checklist Documentation
TruSight Oncology 500 v2.2 Local App Documentation
DRAGEN TruSight Oncology 500 Analysis Software v2.5.2 on ICA Documentation
Custom Protocol Selector
Generates customized, end-to-end instructions